Company Overview of MedImmune, LLC
MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...
One MedImmune Way
Gaithersburg, MD 20878
Founded in 1987
Key Executives for MedImmune, LLC
Vice President of Finance
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Compensation as of Fiscal Year 2015.
MedImmune, LLC Key Developments
MedImmune, LLC Presents at BIO International Convention 2015, Jun-16-2015 02:30 PM
Jun 11 15
MedImmune, LLC Presents at BIO International Convention 2015, Jun-16-2015 02:30 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.
MedImmune, LLC Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 08:40 AM
May 17 15
MedImmune, LLC Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 08:40 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Reginald Seeto, Head of Partnering & Strategy and Vice President.
AstraZeneca and MedImmune Enter into an Exclusive Collaboration with Celgene Corporation for the Development and Commercialisation of MEDI4736
Apr 24 15
AstraZeneca and MedImmune announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma. Under the terms of the agreement, Celgene will make an upfront payment of $450 million to AstraZeneca in relation to MEDI4736. Celgene will lead on development across all clinical trials within the collaboration and will take on all research and development costs until the end of 2016, after which they will take on 75% of these costs. Celgene will also be responsible for global commercialisation of approved treatments. AstraZeneca will continue to manufacture and book all sales of MEDI4736 and will pay a royalty to Celgene on worldwide sales in haematological indications. The royalty rate will start at 70% and will decrease to approximately half of the sales of MEDI4736 in haematological indications over a period of four years. MEDI4736 is an investigational immune checkpoint inhibitor, directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumour's immune-evading tactics. Within
the collaboration, MEDI4736 will be assessed both as monotherapy and in combination with other AstraZeneca and Celgene potential and existing cancer medicines. Over time, the collaboration could expand to include other assets.
Similar Private Companies By Industry
Recent Private Companies Transactions